MedTrace Logo

Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma

NCT00575887 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-12-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of temozolomide on a protracted schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive high grade glioma.

Conditions

Interventions

DRUG

Temozolomide

100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Marmara University

    lead OTHER

Principal Investigators

  • Ufuk ABACIOGLU, MD · Marmara University Hospital, Radiation Oncology Department

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00575887 on ClinicalTrials.gov